Articles by Eric Langer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Eric Langer

Outsourcing Grows in Europe

Aug 1, 2014

Eric Langer of BioPlan Associates describes the development of biopharmaceutical outsourcing in Europe over the past 25 years.

Alternative Expression Systems May Cut Bioprocessing Costs, Open New CMO Opportunities

What manufacturing options will be available for novel expression systems?
Feb 28, 2014

Novel expression systems such as plant-based manufacturing platforms are expected to dramatically lower manufacturing costs. How will the market respond with outsourcing options?

Novel Expression Systems Opening CMO Opportunities

CMOs may find opportunities in alternative expression services.
Feb 2, 2014

CMOs may find opportunities in alternative expression services.

Disposable Applications in Demand for BioPharma

Interest in chromatography innovation continues to decline.
Dec 4, 2013

Interest in chromatography innovation continues to decline.

Disposable Applications in Demand by Biopharma

Interest in chromatography innovation continues to decline.
Nov 2, 2013

Data from BioPlan Associates’ 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production suggest that the interest in disposable devices has begun to extend to biopharma operations beyond basic single-use bags and connectors.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here